Posts

Presentation at the European Society for Medical Oncology Congress 2022 (September 11, 2022; Paris, France): Phase 1/2a study of PRL-02, a long-acting IM depot injection of abiraterone decanoate in patients with prostate cancer (NCT04729114)

Propella Therapeutics, Inc. presented phase 1/2 data of PRL-02 (a long-acting IM depot injection of abiraterone decanoate) for the treatment of advanced prostate cancer at the European Society for Medical Oncology Congress 2022 in Paris, France on September 11, 2022.

Press Release: Propella Therapeutics Announces Presentation of Phase 1/2 Data of PRL-02 for the Treatment of Advanced Prostate Cancer at ESMO Congress 2022

Propella Therapeutics, Inc. announced its presentation of Phase 1/2 data of PRL-02 (a long-acting IM depot injection of abiraterone decanoate) for the treatment of advanced prostate cancer at European Society for Medical Oncology Congress 2022 on September 11, 2022.

Press Release: Propella Therapeutics Announces Licensing Agreement with Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm) for Development and Commercial Rights to CGS-200-5 in Greater China

Propella Therapeutics, Inc. and Jiangsu Aosaikang Pharmaceutical Co. Ltd. announced that the companies have entered into an exclusive licensing agreement for CGS-200-5, a clinical-stage topical treatment that is being developed for the treatment of pain in patients with moderate to severe osteoarthritis of the knee.